These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 23033949)

  • 41. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway.
    Weickhardt AJ; Tebbutt NC; Mariadason JM
    Curr Cancer Drug Targets; 2010 Dec; 10(8):824-33. PubMed ID: 20718704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
    Lemos C; Sack U; Schmid F; Juneja M; Stein U
    Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients.
    Giampieri R; Aprile G; Del Prete M; Faloppi L; Bianconi M; Bonotto M; Fasola G; Cascinu S; Scartozzi M
    Curr Drug Targets; 2014; 15(13):1225-30. PubMed ID: 25382208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
    González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
    Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
    Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP
    Mol Oncol; 2019 Apr; 13(4):725-737. PubMed ID: 30478887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miRNAs as Modulators of EGFR Therapy in Colorectal Cancer.
    Pereira DM; Rodrigues CMP
    Adv Exp Med Biol; 2018; 1110():133-147. PubMed ID: 30623370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.
    Scartozzi M; Pierantoni C; Berardi R; Squadroni M; Cascinu S
    Expert Opin Ther Targets; 2006 Apr; 10(2):281-7. PubMed ID: 16548776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy.
    Villalba M; Evans SR; Vidal-Vanaclocha F; Calvo A
    Cell Tissue Res; 2017 Oct; 370(1):29-39. PubMed ID: 28560691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
    Asghar U; Hawkes E; Cunningham D
    Clin Colorectal Cancer; 2010 Dec; 9(5):274-81. PubMed ID: 21208841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer.
    Ali O; Tolaymat M; Hu S; Xie G; Raufman JP
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33450835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.